The United Kingdom and the United States have forged a landmark commercial pact that will ensure no levies on British pharmaceutical products entering the American market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to raise expenditure on drugs through the National Health Service (NHS). This move ensures that import taxes on these vital goods will remain at nothing for a period of three years.
This agreement is in response to recent warnings to hike duties on branded drug products, with increases floated reaching one hundred percent.
"This agreement between the United Kingdom reinforces the global environment for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. medicine commerce," a statement said.
Economic Impact
Pharmaceuticals represent one of the the United Kingdom's largest exports to the United States, which is by far the biggest destination for major UK drugmakers.
Export figures show that in the 12 months leading up to last September, the UK sold medicines totaling £11.1bn to the US. This value made up 17.4% of all goods exports in that period.
"This deal protects jobs, boosts investment and facilitates the UK to emerge as a global hub for biotech and pharma," a minister commented.
Key UK Commitments
The pact involves several key changes from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to raise overall health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The sum drug companies must pay back to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates topped twenty percent.
Industry Background
This agreement follows a long-running dispute between the drug companies and the ministers over medicine costs and NHS adoption.
These tensions were heightened by arguments that American consumers were paying a premium for the equivalent treatments than consumers in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been halted or cancelled, while major expansions have been directed toward US facilities.
The Science Minister publicly accepted that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the past decade.
